• undefined
      • undefined
    1. Home
    2. People
    3. Solakian, Mark

    Mark Solakian

    Partner

    Boston

    Mark is a go-to advisor for founders, CEOs, and boards across Boston’s life sciences and technology community, known for his practical judgment, calm under pressure, and ability to help rapidly scaling companies and their investors navigate complex, high-impact decisions.

    With more than three decades of experience advising both private and public companies—and having served as a senior in-house executive across multiple pioneering biotech and life sciences companies—Mark brings a uniquely business minded perspective to his counsel and delivers a rare blend of legal acumen and executive experience that positions him as a trusted strategic partner to entrepreneurs, companies and investors.

    Mark is a veteran of hundreds of successful venture capital financings, technology and licensing transactions, strategic alliances, corporate governance matters, mergers and acquisitions, and public and private equity and debt offerings on behalf of companies in every health and biotech related vertical.

    Before joining Orrick, Mark was a partner and co-founder of the Wilson Sonsini Boston office. He previously held senior executive roles at Affymetrix (AFFX), Helicos Biosciences (HLCS) and Joule Global Holdings, where he oversaw legal strategy, led public offerings and financings, negotiated strategic partnerships and licensing transactions, and managed critical business functions including HR, finance, and government affairs.

    Mark and his wife, Christine, have been married for more than 25 years and have two adult children.

    • Representative transactions include the following:

      • TigaTx in multiple rounds of financing and its sale to Epsilogen
      • Prudentia Sciences in its emergence from stealth and funding by Google Ventures, Iaso Ventures and Virtue
      • BioSapien in its Pre-Series A financing led by Global Ventures
      • Doron Therapeutics in its $11M Series A financing led by SPRIM Global Investments
      • GI Windows in its $37M Series B financing led by Orlando Health and joined by Rex Health Ventures and existing investors
      • Fluent BioSciences in multiple rounds of financings led by Samsara Capital and Illumina Ventures and in its sale to Illumina
      • Motif Neurotech in its $18.75M Series A financing led by Arboretum Ventures
      • IVIVA in its sale to United Therapeutics
      • NTx in its $47.5M Series B financing led by RA Capital
      • Aqtual in its $16M Series A financning led by Genoa Ventures, Manta Ray Ventures and Yu Galaxy
      • Glyphic BioTechnologies in its launch and Series A financing led by OMX Ventures
      • Amber Bio in its $26M seed financing led by Andreesen Horowitz Bio+ and Playground Global
      • Neuvivo in its $11M financing led by Prime Street Capital
      • Droplet Biosciences in its launch and $8M seed financing led by The Engine
      • Elucidata in its $16M Series A financing led by Eight Roads Ventures
      • Time BioVentures in its seed funding of Phantom Neuro
      • Think Bioscience in its $17M Seed round led by Innovation Endeavors and Xora Innovation
      • Napigen in its multiple rounds of financing
      • VitroLabs in its $46M Series A financing led by Agronomics
      • ArrePath in its $20M Seed Financing led by Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures
      • Iterative Scopes in its $150M Series B financing led by Insight Partners and Clearlake Capital
      • Aramis Biosciences in its launch and $10.5M Series A led by Safar Partners
      • FREYR in its joint venture with Koch Strategic Platforms
      • Vida Ventures in its $90M Series B financing of Vigil Neuroscience
      • NeuroCycle in its sale to Engrail Therapeurics
      • FREYR in its agreement with 24M to mass produce clean lithium-ion battery cells
      • FREYR in its SPAC transaction with Alussa Energy
      • Libra Therapeutics in its launch and $29M Series A led by Boehringer Ingelheim Venture Fund, Epidarex Capital, and Santé.
      • Vesigen in its launch and $28.5M Series A financing led by Morningside Ventures and Leaps by Bayer
      • Lexent Bio in multiple rounds of financing and its sale to Foundation Medicine
      • Tilos Therapeutics in multiple rounds of financing and its sale to Merck

    News